A detailed history of Rice Hall James & Associates, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 268,337 shares of PCRX stock, worth $5.09 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
268,337
Previous 998,625 73.13%
Holding current value
$5.09 Million
Previous $28.6 Million 85.86%
% of portfolio
0.24%
Previous 1.86%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$11.7 - $28.46 $8.54 Million - $20.8 Million
-730,288 Reduced 73.13%
268,337 $4.04 Million
Q2 2024

Aug 07, 2024

SELL
$25.5 - $31.51 $1.15 Million - $1.42 Million
-44,915 Reduced 4.3%
998,625 $28.6 Million
Q1 2024

Apr 23, 2024

BUY
$27.7 - $35.48 $209,716 - $268,619
7,571 Added 0.73%
1,043,540 $30.5 Million
Q4 2023

Feb 08, 2024

BUY
$26.32 - $34.31 $1.78 Million - $2.32 Million
67,484 Added 6.97%
1,035,969 $35 Million
Q3 2023

Nov 02, 2023

BUY
$30.68 - $40.09 $1.89 Million - $2.47 Million
61,680 Added 6.8%
968,485 $29.7 Million
Q2 2023

Jul 24, 2023

BUY
$36.12 - $47.5 $5.9 Million - $7.75 Million
163,209 Added 21.95%
906,805 $36.3 Million
Q1 2023

May 11, 2023

BUY
$35.53 - $43.38 $10.9 Million - $13.3 Million
306,311 Added 70.05%
743,596 $30.3 Million
Q4 2022

Jan 27, 2023

BUY
$38.19 - $57.45 $1.12 Million - $1.69 Million
29,407 Added 7.21%
437,285 $0
Q3 2022

Nov 01, 2022

SELL
$51.24 - $58.89 $830,190 - $954,135
-16,202 Reduced 3.82%
407,878 $21.7 Million
Q2 2022

Aug 08, 2022

SELL
$51.49 - $81.64 $1.68 Million - $2.67 Million
-32,718 Reduced 7.16%
424,080 $24.7 Million
Q1 2022

May 05, 2022

BUY
$60.03 - $76.49 $2.2 Million - $2.8 Million
36,593 Added 8.71%
456,798 $34.9 Million
Q4 2021

Feb 14, 2022

BUY
$47.97 - $62.21 $4.14 Million - $5.37 Million
86,256 Added 25.83%
420,205 $25.3 Million
Q3 2021

Nov 09, 2021

BUY
$54.64 - $61.3 $189,382 - $212,465
3,466 Added 1.05%
333,949 $18.7 Million
Q2 2021

Jul 29, 2021

SELL
$59.18 - $69.99 $13 Million - $15.3 Million
-219,113 Reduced 39.87%
330,483 $20.1 Million
Q1 2021

May 14, 2021

SELL
$59.31 - $78.82 $257,286 - $341,921
-4,338 Reduced 0.78%
549,596 $38.5 Million
Q4 2020

Feb 16, 2021

SELL
$50.47 - $66.26 $982,852 - $1.29 Million
-19,474 Reduced 3.4%
553,934 $33.1 Million
Q3 2020

Nov 16, 2020

SELL
$51.97 - $63.0 $2.09 Million - $2.53 Million
-40,207 Reduced 6.55%
573,408 $34.5 Million
Q2 2020

Aug 14, 2020

SELL
$30.8 - $52.47 $434,249 - $739,774
-14,099 Reduced 2.25%
613,615 $32.2 Million
Q1 2020

May 15, 2020

BUY
$28.4 - $50.7 $5.99 Million - $10.7 Million
210,863 Added 50.58%
627,714 $21 Million
Q4 2019

Jan 29, 2020

SELL
$36.31 - $46.83 $421,522 - $543,649
-11,609 Reduced 2.71%
416,851 $18.9 Million
Q3 2019

Oct 30, 2019

SELL
$35.66 - $44.99 $287,669 - $362,934
-8,067 Reduced 1.85%
428,460 $16.3 Million
Q2 2019

Aug 01, 2019

SELL
$36.57 - $47.97 $1.01 Million - $1.32 Million
-27,513 Reduced 5.93%
436,527 $19 Million
Q1 2019

May 01, 2019

BUY
$36.47 - $42.17 $445,408 - $515,022
12,213 Added 2.7%
464,040 $17.7 Million
Q4 2018

Feb 14, 2019

BUY
$41.31 - $52.16 $5.06 Million - $6.39 Million
122,569 Added 37.23%
451,827 $19.4 Million
Q3 2018

Oct 25, 2018

SELL
$32.85 - $52.0 $288,225 - $456,248
-8,774 Reduced 2.6%
329,258 $16.2 Million
Q2 2018

Aug 02, 2018

BUY
$27.5 - $39.8 $334,427 - $484,007
12,161 Added 3.73%
338,032 $10.8 Million
Q1 2018

Apr 25, 2018

BUY
$29.98 - $46.35 $63,017 - $97,427
2,102 Added 0.65%
325,871 $10.2 Million
Q4 2017

Jan 23, 2018

BUY
$31.85 - $46.95 $1.6 Million - $2.36 Million
50,335 Added 18.41%
323,769 $14.8 Million
Q3 2017

Oct 30, 2017

BUY
$35.7 - $39.5 $9.76 Million - $10.8 Million
273,434
273,434 $10.3 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $870M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.